FACTBOX-World's top-selling drugs in 2014 vs 2010
April 13 (Reuters) - Roche's (ROG.VX) cancer drug Avastin is expected to be the world's biggest-selling drug in 2014, as today's two top blockbusters -- Lipitor and Plavix -- lose patent protection in 2011 and 2012.
In four years' time, the prescription drug league table will look very different, reflecting the growing commercial dominance of injectable biotech drugs, especially for cancer and rheumatoid arthritis.
Consensus sales forecasts for world's top 10 drugs in 2014: 1. Avastin (cancer) Roche $8.9 bln 2. Humira (arthritis) Abbott (ABT.N) $8.5 bln 3. Enbrel (arthritis) Pfizer(PFE.N)/Amgen(AMGN.O) $8.0 bln 4. Crestor (cholesterol) AstraZeneca (AZN.L) $7.7 bln 5. Remicade (arthritis) Merck(MRK.N)/J&J(JNJ.N) $7.6 bln 6. Rituxan (cancer) Roche $7.4 bln 7. Lantus (diabetes) Sanofi-Aventis (SASY.PA) $7.1 bln 8. Advair (asthma/COPD) GlaxoSmithKline (GSK.L) $6.8 bln 9. Herceptin (cancer) Roche $6.4 bln 10.NovoLog (diabetes) Novo Nordisk (NOVOb.CO) $5.7 bln
Consensus forecasts for 2010: 1. Lipitor (cholesterol) Pfizer $11.7 bln 2. Plavix (anticlotting) Sanofi/Bristol (BMY.N) $9.6 bln 3. Advair (asthma/COPD) GlaxoSmithKline $9.0 bln 4. Remicade (arthritis) Merck/J&J $7.4 bln 5. Enbrel (arthritis) Pfizer/Amgen $7.1 bln 6. Humira (arthritis) Abbott $6.8 bln 7. Avastin (cancer) Roche $6.7 bln 8. Rituxan (cancer) Roche $6.1 bln 9. Diovan (hypertension) Novartis $6.0 bln 10.Crestor (cholesterol) AstraZeneca $5.8 bln
Source: Thomson Reuters
(Reporting by Ben Hirschler, Editing by Sitaraman Shankar)
- Tearful Thai PM urges protesters to take part in election
- Google bus blocked in San Francisco gentrification protest
- North Korea's 'reign of terror' worries South's leader
- Chinese hackers spied on Europeans before G20 meeting: researcher
- Putin dissolves state news agency, tightens grip on Russia media